Decibel Therapeutics, Inc.
DelistedCIK 1656536fmd_070X5B8HJP2SSB75BBG6BTZ1W8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2023, 14 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Research and development | 25 | 30 | 40 |
| Total operating expenses | 40 | 50 | 64 |
| Operating income | (40) | (50) | (64) |
| Interest and investment income | 0 | 0 | 1 |
| Other non-operating income (expense) | 0 | 0 | 1 |
| Income before taxes | (39) | (50) | (63) |
| Income tax expense | 0 | 2 | 0 |
| Net income from continuing operations | (39) | (52) | (63) |
| Net income | (39) | (52) | (63) |
| Net income to common shareholders | 7 | (54) | (63) |